First-in-class peptide drug based on IDDT platform technology
New drug development company.
REMEDI was established in 2020 and aimed to develop new drugs using the Intra-cellular Drug Delivery Technology (IDDT) platform.
Cell penetrating peptides found based on IDDT platform can be attached to peptides, proteins, RNA, DNA, etc. to increase efficency and reduce toxicity.
All executives and employees will do their best to improve human life through effective and innovative drug development.
Chanho Park C.E.O.